The Cancer Center Director has the responsibility and authority to set priorities and to develop new programs for the Cancer Center. Faculty and senior leadership are the primary drivers in developing the focus of new research areas. External consultants and seminar speakers provide new perspectives on emerging areas of research and provide useful advice for possible future research directions. The Cancer Center leadership and several internal advisory groups serve to develop a specific set of goals from identified opportunities and available resources. The External Scientific Advisory Committee (EXSAC) meets each spring to review existing programs and proposed recruitment and scientific targets that have been developed by the senior leadership and faculty. These discussions inform the recruitment targets and planning efforts that begin each fall. Once new research goals are set, faculty are encouraged to pursue and support these goals through incentives that include pilot project funding, research instrumentation purchases, development of shared facilities, and recruitment of new faculty who are potential collaborators. Identification of shared facility and common equipment needs originates with the investigators and their laboratory staff, and is integrated at the level of the Internal Steering and Shared Resources Committees. Program members serving on recruitment committees identify and recommend the selection of new faculty, who bring to the Cancer Center new research areas, technologies, and opportunities for collaboration. The main internal advisory bodies include: i) the Cancer Center Executive Committee, ii) the Internal Steering Committee, iii) the Membership Committee and iv) the Shared Resources Committee. The External Scientific Advisory Committee (EXSAC) currently has 10 members representative of a broad spectrum of cancer research. Funding in the amount of $10,000 is requested for the annual meeting of the EXSAC;$5,000 is requested for the annual Cancer Center member retreat, and $6,000 is requested for planning and evaluation meetings for the Scientific Program groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-42
Application #
8233464
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
42
Fiscal Year
2011
Total Cost
$36,616
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications